1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
United States
(512) 598-0931
https://www.anebulo.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman | 11k | N/A | 1972 |
Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer | 425.15k | N/A | 1959 |
Mr. Richard Anthony Cunningham | CEO & Director | N/A | N/A | 1971 |
Mr. Daniel V. George | Principal Accounting Officer, Acting CFO & Secretary | N/A | N/A | 1970 |
Mr. Scott L. Anderson | Head of Investor Relations & Public Affairs | N/A | N/A | N/A |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.